Meeting
2022 ASCO Annual Meeting
Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.
Authors
Ilana Mandel
Biond Biologics, Misgav, Israel
Ilana Mandel , Rui Wang , Anne Caron , Eladio Marquez , Colette Dib , Donald Jackson , Cecilia Deantonio , Dana Haves , Ilana Goldshtein , Tsuri Peretz , Dror Alishekevitz , Sharon Hashmueli , Yair Sapir , Tehila Ben Moshe , Giovanni Abbadessa , Itay Friedman , Nigel Crawford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2571)
DOI
10.1200/JCO.2022.40.16_suppl.2571
Abstract #
2571
Poster Bd #
226
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2022 ASCO Annual Meeting
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
First Author: Niki Gavrielatou
Poster
2022 ASCO Annual Meeting
Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs).
First Author: Lisa K. Blum
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer.
First Author: Sarabjot Pabla